InsiderTrades.com logo
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.
Andrew D. Dickinson net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Andrew Dickinson Biography and Net Worth

CFO of Gilead Sciences

Andrew Dickinson serves as Gilead's Chief Financial Officer, responsible for the oversight of the company’s global finance, corporate development, information technology, operations and strategy organizations.

Andy joined Gilead in 2016 and prior to his current role served as head of the company’s corporate development and strategy group. In that role, Andy drove all of Gilead’s licensing, partnership and acquisition transactions and guided investments into new areas. Prior to his tenure at Gilead, Andy was the global Co-Head of Healthcare Investment Banking at Lazard. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen, Inc., which was acquired by Gilead in 2006.

Andy received his bachelor’s degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and his law degree from Loyola University of Chicago.

What is Andrew D. Dickinson's net worth?

The estimated net worth of Andrew D. Dickinson is at least $6.64 million as of January 16th, 2024. Mr. Dickinson owns 101,534 shares of Gilead Sciences stock worth more than $6,642,354 as of April 27th. This net worth approximation does not reflect any other investments that Mr. Dickinson may own. Additionally, Mr. Dickinson receives a salary of $2,660,000.00 as CFO at Gilead Sciences. Learn More about Andrew D. Dickinson's net worth.

How old is Andrew D. Dickinson?

Mr. Dickinson is currently 54 years old. There are 7 older executives and no younger executives at Gilead Sciences. The oldest executive at Gilead Sciences is Dr. Rudolf Ertl, Senior Vice President of Commercial Operations of Australia, Canada, Europe, who is 78 years old. Learn More on Andrew D. Dickinson's age.

What is Andrew D. Dickinson's salary?

As the CFO of Gilead Sciences, Inc., Mr. Dickinson earns $2,660,000.00 per year. There are 3 executives that earn more than Mr. Dickinson. The highest earning executive at Gilead Sciences is Mr. Daniel P. O'Day, Chairman & CEO, who commands a salary of $6,990,000.00 per year. Learn More on Andrew D. Dickinson's salary.

How do I contact Andrew D. Dickinson?

The corporate mailing address for Mr. Dickinson and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Andrew D. Dickinson's contact information.

Has Andrew D. Dickinson been buying or selling shares of Gilead Sciences?

Andrew D. Dickinson has not been actively trading shares of Gilead Sciences during the past quarter. Most recently, Andrew D. Dickinson sold 5,000 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a transaction totalling $428,900.00. Following the completion of the sale, the chief financial officer now directly owns 101,534 shares of the company's stock, valued at $8,709,586.52. Learn More on Andrew D. Dickinson's trading history.

Who are Gilead Sciences' active insiders?

Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.

Are insiders buying or selling shares of Gilead Sciences?

In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 30,228 shares worth more than $2,453,404.15. The most recent insider tranaction occured on April, 1st when insider Merdad Parsey sold 2,000 shares worth more than $145,920.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.

Information on this page was last updated on 4/1/2024.

Andrew D. Dickinson Insider Trading History at Gilead Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2024Sell5,000$85.78$428,900.00101,534View SEC Filing Icon  
10/17/2023Sell5,000$80.00$400,000.00104,003View SEC Filing Icon  
7/20/2023Sell5,000$80.00$400,000.00107,587View SEC Filing Icon  
See Full Table

Andrew D. Dickinson Buying and Selling Activity at Gilead Sciences

This chart shows Andrew D Dickinson's buying and selling at Gilead Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gilead Sciences Company Overview

Gilead Sciences logo
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $65.42
Low: $64.63
High: $66.35

50 Day Range

MA: $71.28
Low: $65.27
High: $75.94

2 Week Range

Now: $65.42
Low: $64.63
High: $87.86

Volume

12,349,126 shs

Average Volume

6,443,315 shs

Market Capitalization

$81.45 billion

P/E Ratio

181.72

Dividend Yield

4.72%

Beta

0.19
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.